Using exosomes to switch myeloid cells

Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer

Driven by the natural biology of exosomes, Codiak has moved beyond diagnostics and targeted cancer therapies to embrace myeloid switching as a strategy to treat cancer.

The biotech presented preclinical data Nov. 18 at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy showing that ASO-carrying exosome therapies can

Read the full 525 word article

User Sign In